Legal

Last Updated: February 17, 2025

We conduct research to advance scientific understanding of Alzheimer’s risk, cognitive health, and the impact of early intervention protocols such as the BAT Pill Protocol™. Research is part of our mission to transform Alzheimer’s prevention through data-driven insights from patients like you.

1.1 Automatic Enrollment in BATWatch Research

By receiving Silver House services, such as our BATWatch program, you are automatically enrolled in Silver House Research. Participation is part of our commitment to continuous improvement and advancing Alzheimer’s prevention.

You will be asked to acknowledge this Research Consent during onboarding.

You may opt out of research participation at any time without losing access to Silver House services or treatments.

1.2 Key Information:

The purpose of Silver House Research is to identify patterns in cognitive biomarkers, genetic risk factors, and treatment outcomes to advance Alzheimer’s prevention and cognitive health.

By participating, you allow Silver House researchers to use your de-identified health data, including BAT Level results, genetic risk assessments, treatment outcomes, survey responses, and cognitive assessments.

Silver House Research may be conducted in collaboration with third parties such as non-profit organizations, academic institutions, or pharmaceutical companies.

Your privacy is protected: All research uses de-identified data that has been stripped of personal information (e.g., name, contact details) and combined with data from other participants.

You will not directly receive compensation or individual results from participation, but your contribution may help improve future treatments and guide Silver House’s clinical protocols.

Participation is entirely voluntary. Your access to Silver House testing, treatments, or services will not be affected by your choice to participate or withdraw from research.

1.3 Purpose: Why is BATWatch Conducting Research?

Silver House Research aims to:

• Identify Risk Factors: Study how BAT Levels, genetic predisposition, and lifestyle factors influence Alzheimer’s risk.

• Improve Early Detection: Refine testing protocols to detect cognitive risk earlier and more accurately.

• Advance Treatment: Assess the effectiveness of interventions such as the BAT Pill Protocol in lowering risk and preventing neurodegeneration.

• Guide Future Protocols: Use insights to improve Silver House services and develop more personalized cognitive health plans.

Examples of Research Outcomes:

• Identifying patterns linking BAT Levels with early Alzheimer’s risk.

• Studying patient outcomes from the BAT Pill Protocol.

• Analyzing treatment response differences by APOE4 status or other risk factors.

• Contributing to peer-reviewed publications or collaborating with institutions to advance Alzheimer’s prevention.

1.4 What Does Participation Involve?

By agreeing to participate in Silver House Research, you consent to Silver House using the
following de-identified data for research purposes:

• Cognitive Biomarkers: Your BAT Level results and genetic risk assessment data.

• Treatment Outcomes: Data from your participation in protocols such as the BAT Pill Protocol.

• Self-Reported Information: Surveys, questionnaires, and health history you choose to provide.

• Digital Interaction Data: Information on how you engage with the BATWatch platform, educational materials, and tools.

• Third-Party Data: Information you authorize us to collect from lab partners (e.g., Quest Diagnostics) or wearable devices you connect to the platform.

1.5 Research Participation is Separate from Your Medical Care

• You are not required to participate in Silver House Research to receive services.

• Participation will not affect your access to the BAT Pill Protocol or other treatments.

• Research participation is separate from Silver House’s clinical operations, and your treating provider will not know your research status.

1.6 Research Collaborations and Publications

• Research findings may be published in scientific journals or presented at conferences.

• We may collaborate with third parties (e.g., universities, pharmaceutical partners) to further Alzheimer’s prevention research.

• Shared results will only be in aggregate form and will never identify you individually.

• We may share information with our ethics review board (also called an Institutional Review Board or “IRB”) and other agencies to maintain our compliance, or as otherwise required by law.

1.7 Data Protection and Privacy

• Your identifiable information is kept separate from research data.

• Research uses only de-identified data combined with other participants’ information.

• We will never share your identifiable health information without your explicit authorization, except as required by law.

1.8 Voluntary Participation & Withdrawal Rights

Your participation in Silver House Research is automatic as part of your services. Participation is entirely voluntary, and you may revoke your consent at any time without affecting your access to BATWatch testing or treatments. Your decision to participate or withdraw from research will not affect your medical care.

Participation is voluntary and can be withdrawn at any time via your account settings or by contacting our Research Team.

Withdrawing consent stops your data from being used in future research but does not remove data from ongoing or completed studies.

Withdrawal does not affect your medical care, Silver House services, or access to treatments.

1.9 Contact Information for Research-Related Questions:

Silver House Research Team: ops [at] silverhouse [dot] health

Silver House Care Team: 1-202-681-1274